Render Target: STATIC
Render Timestamp: 2024-11-15T10:13:52.891Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:59:29.872
Product last modified at: 2024-09-30T08:00:51.984Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

EMCN (E3Z4D) Rabbit mAb #96380

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 95-110
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:1000 - 1:4000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #89278.

    Protocol

    Specificity / Sensitivity

    EMCN (E3Z4D) Rabbit mAb recognizes endogenous levels of total EMCN protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human EMCN protein.

    Background

    Endomucin (EMCN) is a type I transmembrane O-sialoglycoprotein expressed in endothelium in venules and capillaries, but not arteries (1,2). EMCN prevents leukocyte adhesion in non-inflamed tissues, and downregulation of EMCN during inflammation facilitates migration of inflammatory cells into target tissues (3). Notch activation in endothelial cells downregulates EMCN and promotes migration of neutrophils, modulating acute inflammation in hepatic ischemia/reperfusion injury (4). EMCN deficiency in endothelial cells drives tumor lung metastasis by providing a premetastatic niche for cancer cell colonization, and is a potential prognostic biomarker for highly metastatic cancers (5). Combined analysis of EMCN/MUC15 has been suggested as a prognostic signature for gastric cancer (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.